Delayed
Toronto S.E.
03:46:29 2024-05-14 pm EDT
|
5-day change
|
1st Jan Change
|
0.06
CAD
|
+200.00%
|
|
+140.00%
|
+500.00%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
0.1603
|
0.3043
|
0.6245
|
0.7672
|
0.3172
|
0.1299
|
Enterprise Value (EV)
1 |
0.1579
|
0.2933
|
0.5453
|
0.7581
|
0.3168
|
0.1292
|
P/E ratio
|
-2.94
x
|
-
|
-11.5
x
|
-12.8
x
|
-4.96
x
|
-2.24
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
13
x
|
-2.44
x
|
5.85
x
|
-6.18
x
|
-5.01
x
|
4
x
|
FCF Yield
|
7.71%
|
-41%
|
17.1%
|
-16.2%
|
-19.9%
|
25%
|
Price to Book
|
-1.2
x
|
-
|
-6.48
x
|
-9.45
x
|
-4.79
x
|
-1.02
x
|
Nbr of stocks (in thousands)
|
8,758
|
13,258
|
13,258
|
15,258
|
17,258
|
17,258
|
Reference price
2 |
0.0183
|
-
|
0.0471
|
0.0503
|
0.0184
|
0.007529
|
Announcement Date
|
4/16/19
|
4/29/20
|
3/25/21
|
4/22/22
|
4/21/23
|
4/19/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-0.0546
|
-0.0514
|
-0.0545
|
-0.06
|
-0.0631
|
-0.046
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-0.0546
|
-0.0635
|
-0.0545
|
-0.06
|
-0.0631
|
-0.0581
|
Net income
1 |
-0.0546
|
-0.0635
|
-0.0545
|
-0.06
|
-0.0631
|
-0.0581
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.006236
|
-0.005643
|
-0.004113
|
-0.003939
|
-0.003706
|
-0.003367
|
Free Cash Flow
1 |
0.0122
|
-0.1201
|
0.0933
|
-0.1226
|
-0.0632
|
0.0323
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
4/16/19
|
4/29/20
|
3/25/21
|
4/22/22
|
4/21/23
|
4/19/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
0
|
0.01
|
0.08
|
0.01
|
0
|
0
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
0.01
|
-0.12
|
0.09
|
-0.12
|
-0.06
|
0.03
|
ROE (net income / shareholders' equity)
|
49%
|
74.2%
|
81.6%
|
67.5%
|
85.5%
|
60.2%
|
ROA (Net income/ Total Assets)
|
-1,411%
|
-387%
|
-71.8%
|
-80.9%
|
-572%
|
-1,083%
|
Assets
1 |
0.003872
|
0.0164
|
0.076
|
0.0741
|
0.011
|
0.005367
|
Book Value Per Share
2 |
-0.0200
|
-0
|
-0.0100
|
-0.0100
|
-0
|
-0.0100
|
Cash Flow per Share
2 |
0
|
0
|
0.0100
|
0
|
0
|
0
|
Capex
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
4/16/19
|
4/29/20
|
3/25/21
|
4/22/22
|
4/21/23
|
4/19/24
|
|
1st Jan change
|
Capi.
|
---|
| +500.00% | 759K | | -27.01% | 9.96B | | -8.58% | 3.03B | | +31.86% | 3B | | -13.62% | 2.18B | | -16.32% | 1.76B | | +63.36% | 1.42B | | +27.00% | 794M | | -2.18% | 756M | | +3.18% | 305M |
Bio Diagnostics & Testing
|